Documents
Federal rules and notices from the public comment record, analyzed continuously.
FDA ▾
Effectiveness of Anthelmintics: Specific Recommendations for Equines; VICH GL15; Guidance for Industry; Final Guidance; #109
0 comments
Analysis in progress
Top issues in comments
Effectiveness of Anthelmintics: Specific Recommendations for Felines; VICH GL20; Guidance for Industry; Final Guidance; #113
0 comments
Analysis in progress
Top issues in comments
Effectiveness of Anthelmintics: Specific Recommendations for Bovines; VICH GL12; Guidance for Industry; Final Guidance; #95
0 comments
Analysis in progress
Top issues in comments
Topical Dermatologic Corticosteroids: In Vivo Bioequivalence; Guidance for Industry; Final Guidance
0 comments
Analysis in progress
Top issues in comments
Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications Guidance for Industry, IRBs, and Clinical Investigators
0 comments
Analysis in progress
Top issues in comments
Cancer Clinical Trial Eligibility Criteria: Performance Status Guidance for Industry, IRBs, and Clinical Investigators
0 comments
Analysis in progress
Top issues in comments
Cancer Clinical Trial Eligibility Criteria: Laboratory Values; Guidance for Industry, IRBs, and Clinical Investigators
0 comments
Analysis in progress
Top issues in comments
Yong Sheng Jiao: Denial of Application for Termination of Debarment
0 comments
Analysis in progress
Top issues in comments
Determination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
0 comments
Analysis in progress
Top issues in comments
Determination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
0 comments
Analysis in progress
Top issues in comments
Determination of Regulatory Review Period for Purposes of Patent Extension; BLUJEPA
0 comments
Analysis in progress
Top issues in comments
NOOH Letter from FDA OII to Yayun Chen
0 comments
Analysis in progress
Top issues in comments